You are here

type 2 diabetes

Regulus reports a trio of pipeline setbacks

Regulus reports a trio of pipeline setbacks

BioPharma Dive

cholestatic disease

type 2 diabetes

Flag link:

Johnson & Johnson's Analyst Day Was Overshadowed by This Worrisome Data

Johnson & Johnson's Analyst Day Was Overshadowed by This Worrisome Data

Motley Fool

type 2 diabetes

Flag link:

FDA Adds Boxed Warning to Janssen's Type 2 Diabetes Drug Label

FDA Adds Boxed Warning to Janssen's Type 2 Diabetes Drug Label

RAPS.org

type 2 diabetes

Flag link:

Novo Nordisk launches Xultophy diabetes therapy in U.S.

Novo Nordisk launches Xultophy diabetes therapy in U.S.

Mass Device

type 2 diabetes

insulin degludec

Flag link:

MannKind Hopes To Reverse Fortunes With Television Show

MannKind Hopes To Reverse Fortunes With Television Show

Seeking Alpha

type 2 diabetes

DTC advertising

Flag link:

Virta Health looks to reverse, not treat, Type II diabetes

Virta Health looks to reverse, not treat, Type II diabetes

Drug Delivery Business News

type 2 diabetes

Flag link:

Merck, Pfizer line up a big FDA decision on a blockbuster hopeful, staring down some major league competition

Merck, Pfizer line up a big FDA decision on a blockbuster hopeful, staring down some major league competition

Endpoints

type 2 diabetes

Flag link:

J&J touts NEJM publication of 5-year Type II diabetes bariatric surgery study

J&J touts NEJM publication of 5-year Type II diabetes bariatric surgery study

Mass Device

type 2 diabetes

bariatric surgery

Flag link:

FDA Clears New Tool for Patients with Type 2 Diabetes

FDA Clears New Tool for Patients with Type 2 Diabetes

Qmed

type 2 diabetes

blood glucose monitoring

Flag link:

Lilly Shares Spike On Jardiance Approval (LLY)

Lilly Shares Spike On Jardiance Approval (LLY)

Investopedia

type 2 diabetes

cardiovascular death

Flag link:

Johnson & Johnson Gets FDA Approval for Type 2 Diabetes Drug

Johnson & Johnson Gets FDA Approval for Type 2 Diabetes Drug

Market Realist

type 2 diabetes

Flag link:

U.S. FDA expands indication for type 2 diabetes treatment Synjardy to include treatment-naïve adults

U.S. FDA expands indication for type 2 diabetes treatment Synjardy to include treatment-naïve adults

Yahoo

type 2 diabetes

Flag link:

New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes

New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes

Yahoo

type 2 diabetes

Boehringer Ingelheim

Flag link:

AstraZeneca Presents New Data from Multiple Studies on the Effect of BYDUREON on Glucose Fluctuations in Patients with Type 2 Diabetes

AstraZeneca Presents New Data from Multiple Studies on the Effect of BYDUREON on Glucose Fluctuations in Patients with Type 2 Diabetes

Yahoo

clinical trials

type 2 diabetes

Flag link:

Diabetes 'Unicorn' Intarcia Hits Major Milestone

Diabetes 'Unicorn' Intarcia Hits Major Milestone

Fortune

type 2 diabetes

Flag link:

Zafgen Soars on Positive Phase 2 Results

Zafgen Soars on Positive Phase 2 Results

24/7 Wall St

clinical trials

type 2 diabetes

Flag link:

Sanofi Reports Positive Top-Line Results in Second Pivotal LixiLan Phase III Study

Sanofi Reports Positive Top-Line Results in Second Pivotal LixiLan Phase III Study

Yahoo

type 2 diabetes

Flag link:

Bad News Type 2 Diabetics: The FDA Is Out With Another Warning

Bad News Type 2 Diabetics: The FDA Is Out With Another Warning

Motley Fool

type 2 diabetes

DPP-4 inhibitor

SGLT2 inhibitor

Flag link:

Intarcia’s diabetes treatment beats $6B Merck drug in head-to-head trial

Intarcia’s diabetes treatment beats $6B Merck drug in head-to-head trial

Bizjournals.com

type 2 diabetes

Flag link:

Sanofi's diabetes combo clears a clinical hurdle in a race with Novo Nordisk

Sanofi's diabetes combo clears a clinical hurdle in a race with Novo Nordisk

Fierce Biotech

type 2 diabetes

Flag link: